Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: communication

Rheumatology Drug Updates on Brentuximab Vedotin, Tofacitinib Citrate

Michele B. Kaufman, PharmD, BCGP  |  November 17, 2015

Brentuximab Vedotin Enters Phase 2 Trials Brentuximab vedotin (Adcetris), an antibody-drug conjugate (ADC) directed at CD30, is currently entering Phase 2 clinical trials for treating systemic lupus erythematosus (SLE).1 The ADC encompasses an anti-CD30 monoclonal antibody, which is attached by a protease-cleavable linker to a microtubule-disrupting agent, known as monomethyl auristatin E (MMAE). The ADC…

Filed under:Drug Updates Tagged with:Brentuximab vedotinDisease-modifying antirheumatic drugs (DMARDs)DrugsFDAhydroxyureaMRIrheumatologySafetytofacitinib citrate

Rheumatologist Steven S. Overman Reflects on His Last Day of Practice, Future of Specialty

Steven S. Overman, MD, MPH • illustrations by Alice C. Gray  |  November 16, 2015

I am a few weeks post-retirement. Having written thank you notes and completed urgent home projects, I swing in a hammock at our currently fire-threatened cabin north of Winthrop, Wash., and reflect. I feel like a young boy while freely flipping pages of a hand-scribed picture book, The Principles of Uncertainty, by Maira Kalman. She…

Filed under:Practice SupportProfiles Tagged with:Profileretirementrheumatologistrheumatology practice

Patients OK with Secure Web Portals for Test Results

Lisa Rapaport  |  November 15, 2015

(Reuters Health)—Of all the ways for patients to receive their medical test results, one option—password-protected websites—appears to be preferred much of the time, a study suggests. U.S. researchers surveyed about 400 adults and found they were generally comfortable with web portals regardless of how sensitive the test results might be. This was among the most…

Filed under:EMRsTechnology Tagged with:patient communicationtestswebsite

RA Drug Tested & FDA Orders Drug-Interaction Studies for Kayexalate

Michele B. Kaufman, PharmD, BCGP  |  November 11, 2015

In multiple trials, baricitinib has proved promising for treating RA. Also, the FDA is requiring drug-interaction studies for sodium polystyrene sulfonate…

Filed under:Biologics/DMARDsDrug Updates Tagged with:baricitinibdrug interactionFDAFood and Drug Administrationsodium polystyrene sulfonate

Online Tool Helps RA Patients Make Informed Decisions

Arthritis Care & Research  |  November 3, 2015

Should you escalate care to a biologic? Many RA patients find this decision difficult and may need extra support and education to come to an informed decision. A recent study on this issue tested the value of a Web-based interactive decision support tool, which was developed with patient and physician input. After eight weeks, patients using the tool showed a measurable increase in the objective and subjective knowledge needed for making an informed decision compared with standard care…

Filed under:ConditionsResearch RheumRheumatoid ArthritisTechnology Tagged with:Arthritis Care & Researchbiologic drugsonline educationpatient communicationpatient education

FDA Warns ‘Don’t Use Tramadol in Children’ & More

Michele B. Kaufman, PharmD, BCGP  |  October 21, 2015

New studies show ABT-494 is an effective alternative to anti-TNF alpha agents, as well as methotrexate, for RA. Also, the FDA issued a warning against using tramadol for young patients due to their increased risk of respiratory side effects…

Filed under:Drug Updates

anaken2012/shutterstock.com

Legalities of Telemedicine

Kathy Holliman, MEd  |  October 15, 2015

A brief has been filed with the U.S. Supreme Court that, if the court decides to hear the case, could have wide-ranging implications for online medical care and the limits of a physician’s First Amendment right to free speech. Medical Advice Via e-Mail Institute for Justice Senior Attorney Jeff Rowes filed the brief at the…

Filed under:Legal UpdatesPractice SupportProfessional TopicsTechnology Tagged with:ConsultationLegalpatient carePractice ManagementrheumatologyTechnologytelemedicine

Opinion: Insurance Companies Use Medically and Fiscally Irresponsible Formularies

Bruce Rothschild, MD  |  October 14, 2015

Receipt of an unsolicited communication that a sweepstakes award has been won may con some people (especially, but not limited to, those underprivileged or undereducated as to legalities), but can’t fool all of the people all of the time. The names of the organizations and products involved are often marketing tool inventions, which imply special…

Filed under:EthicsInsuranceLegal UpdatesProfessional Topics Tagged with:formulariesinsuranceLegalrheumatology

FDA Issues Stronger Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Warning

Michele B. Kaufman, PharmD, CGP, RPh  |  October 14, 2015

The U.S. Food and Drug Administration (FDA) has toughened the existing warnings for nonsteroidal anti-inflammatory drugs (NSAIDs) due to their stroke and myocardial infarction (MI) risk increase.1 Due to a continual review of these products, FDA is requiring label updates for all prescription NSAIDs. Over-the-counter (OTC) NSAIDs already list the increased risk of MI and…

Filed under:ConditionsDrug UpdatesOther Rheumatic ConditionsResearch Rheum Tagged with:abaloparatideadverse eventsanti-inflammatoryclinical trialsdrugFDAMIMyocardial infarctionnonsteroidal anti-inflammatory drugsNSAIDsoutcomeResearchrheumatologyriskSafetystroketofacitinib citrate

Ethics Forum: Personal Ethics Questions Surrounding RheumPAC Donations

Matthew L. Mundwiler, MD, & Robert H. Shmerling, MD  |  October 14, 2015

Imagine you’ve just heard a compelling presentation urging all ACR members to contribute to RheumPAC, the ACR’s political action committee. RheumPAC’s mission is to support politicians who support issues important to rheumatologists. You are impressed by the role RheumPAC has played in a number of issues you support. Just as you’re writing a check, you…

Filed under:EthicsLegislation & AdvocacyProfessional Topics Tagged with:AdvocacydonationsEthicsLegislationPoliticsrheumatologistsrheumatologyRheumPAC

  • « Previous Page
  • 1
  • …
  • 63
  • 64
  • 65
  • 66
  • 67
  • …
  • 95
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences